These findings highlight the therapeutic potential of targeting NF-κB and MAPK signaling to mitigate cytokine storms in EBV-HLH (Fig. 5h) and related hyperinflammatory syndromes. This evidence concerns the gene NFKB1 and hemophagocytic syndrome.